


TNG260

Chemical Properties

CAS No. : 2935964-98-8
Formula: C₂₀H₁₈N₃O₂S
Molecular Weight: 383.44
Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	TNG260 is a selective and orally effective inhibitor of HDAC1 and the CoREST complex, exhibiting 10-fold selectivity for HDAC1 over HDAC3 and 500-fold selectivity for CoREST over NuRD and Sin3 complexes. TNG260 reshapes the tumor immune microenvironment by reducing immunosuppressive neutrophil infiltration, enhancing effector T-cell recruitment, reversing anti-PD-1 resistance driven by STK11 deficiency, and inducing durable tumor regression in combination with α -PD-1 in STK11-mutant MC38 tumor models while maintaining lower bone marrow toxicity than non-selective HDAC inhibitors.
Targets(IC50)	HDAC
In vivo	In syngeneic and Genetically Engineered Mouse Models (GEMM) of STK11-mutant NSCLC, TNG260 was evaluated in combination with anti-PD1 therapy. This combination inhibited tumor growth in KRAS/STK11 mutant NSCLC tumors. The treatment modulated the tumor microenvironment, characterized by increased markers of macrophages, neutrophils, and dendritic cells within the tumor. No toxicity was observed in the mice [2].

Solubility Information

Solubility	DMSO: 1.7 mg/mL (4.43 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.608 mL	13.0398 mL	26.0797 mL
5 mM	0.5216 mL	2.608 mL	5.2159 mL
10 mM	0.2608 mL	1.304 mL	2.608 mL
50 mM	0.0522 mL	0.2608 mL	0.5216 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ahronian L, et al. TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11[J]. *J Immunother*, 2022, 10(2): A1-A1595.

Patel Ayushi, et al. TNG260, a small molecule CoREST inhibitor, sensitizes STK11-mutant NSCLC to anti-PD1 immunotherapy. *Cancer Research* 84. 6_Supplement (2024): 3916-3916.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481